激酶抑制剂-话题@MedSci

#激酶抑制剂#

80篇内容 | 2595人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2039909, encodeId=9b3b203990939, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, objectType=article, longId=194626, objectId=133519462630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=133519462630, replyNumber=0, likeNumber=123, createdTime=2021-03-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=133519462630, moduleTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=133519462630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039908, encodeId=0db7203990894, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌, objectType=article, longId=192476, objectId=9a771924e693, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a771924e693, replyNumber=0, likeNumber=87, createdTime=2020-09-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a771924e693, moduleTitle=FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a771924e693)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039913, encodeId=eb402039913cc, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=多激酶抑制剂ON 123300治疗复发/难治性晚期癌症：即将开展I期临床研究, objectType=article, longId=203706, objectId=f94a203e06d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f94a203e06d6, replyNumber=0, likeNumber=72, createdTime=2021-11-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f94a203e06d6, moduleTitle=多激酶抑制剂ON 123300治疗复发/难治性晚期癌症：即将开展I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f94a203e06d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039910, encodeId=0d322039910ff, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Clin Cancer Res：WEE1激酶抑制剂adavosertib联合化疗治疗TP53突变型卵巢癌, objectType=article, longId=199405, objectId=b6411994055d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6411994055d, replyNumber=0, likeNumber=91, createdTime=2020-09-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6411994055d, moduleTitle=Clin Cancer Res：WEE1激酶抑制剂adavosertib联合化疗治疗TP53突变型卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6411994055d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039906, encodeId=811f203990674, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=英国NICE推荐将辉瑞的细胞周期蛋白依赖性激酶抑制剂Ibrance用于治疗晚期或转移性乳腺癌, objectType=article, longId=184022, objectId=bfe4184022fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfe4184022fb, replyNumber=0, likeNumber=111, createdTime=2019-12-13, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfe4184022fb, moduleTitle=英国NICE推荐将辉瑞的细胞周期蛋白依赖性激酶抑制剂Ibrance用于治疗晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfe4184022fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039903, encodeId=d9a020399039f, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Seattle Genetics的酪氨酸激酶抑制剂tucatinib治疗晚期或转移性乳腺癌临床试验成功, objectType=article, longId=181705, objectId=c214181e05e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c214181e05e3, replyNumber=0, likeNumber=90, createdTime=2020-06-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c214181e05e3, moduleTitle=Seattle Genetics的酪氨酸激酶抑制剂tucatinib治疗晚期或转移性乳腺癌临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c214181e05e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039907, encodeId=0a9f203990e24, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗, objectType=article, longId=188797, objectId=3aed188e972f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3aed188e972f, replyNumber=0, likeNumber=75, createdTime=2020-12-29, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3aed188e972f, moduleTitle=武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3aed188e972f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039904, encodeId=69f32039904b8, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=酪氨酸激酶抑制剂治疗胃肠间质瘤不良反应及处理共识, objectType=article, longId=182536, objectId=5f991825361e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f991825361e, replyNumber=0, likeNumber=49, createdTime=2020-04-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f991825361e, moduleTitle=酪氨酸激酶抑制剂治疗胃肠间质瘤不良反应及处理共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f991825361e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039896, encodeId=848420398969e, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Ann Rheum Dis：Janus激酶抑制剂对类风湿性关节炎患者心血管事件风险的影响, objectType=article, longId=166417, objectId=58c816641e1e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58c816641e1e, replyNumber=0, likeNumber=65, createdTime=2019-07-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58c816641e1e, moduleTitle=Ann Rheum Dis：Janus激酶抑制剂对类风湿性关节炎患者心血管事件风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58c816641e1e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039901, encodeId=91ef203990139, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Lancet oncol：第三代酪氨酸激酶抑制剂（lazertinib）治疗晚期NSCLC, objectType=article, longId=180842, objectId=a90e180842c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a90e180842c3, replyNumber=0, likeNumber=71, createdTime=2020-07-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a90e180842c3, moduleTitle=Lancet oncol：第三代酪氨酸激酶抑制剂（lazertinib）治疗晚期NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a90e180842c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039905, encodeId=507a2039905aa, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Sci Rep：细胞减灭肾切除术围术期使用酪氨酸激酶抑制剂的相关并发症研究, objectType=article, longId=182845, objectId=9a5518284533, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a5518284533, replyNumber=0, likeNumber=73, createdTime=2020-06-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a5518284533, moduleTitle=Sci Rep：细胞减灭肾切除术围术期使用酪氨酸激酶抑制剂的相关并发症研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a5518284533)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039902, encodeId=9bda2039902b9, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定, objectType=article, longId=181137, objectId=82d718113e9c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82d718113e9c, replyNumber=0, likeNumber=78, createdTime=2019-12-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82d718113e9c, moduleTitle=勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82d718113e9c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039900, encodeId=753d203990001, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=J Thromb Haemost：接受细胞周期依赖性激酶抑制剂治疗的乳腺癌患者静脉血栓栓塞风险, objectType=article, longId=178847, objectId=33041e884710, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33041e884710, replyNumber=0, likeNumber=101, createdTime=2020-03-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33041e884710, moduleTitle=J Thromb Haemost：接受细胞周期依赖性激酶抑制剂治疗的乳腺癌患者静脉血栓栓塞风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33041e884710)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039898, encodeId=280f2039898ad, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=NICE推荐将激酶抑制剂neratinib用作乳腺癌的新辅助治疗, objectType=article, longId=177327, objectId=749f1e732700, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=749f1e732700, replyNumber=0, likeNumber=77, createdTime=2019-10-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=749f1e732700, moduleTitle=NICE推荐将激酶抑制剂neratinib用作乳腺癌的新辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=749f1e732700)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039895, encodeId=cc7920398957f, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=成纤维细胞生长因子受体酪氨酸激酶抑制剂E7090治疗胆管癌，获得日本厚生劳动省的Sakigake指定, objectType=article, longId=163899, objectId=93891638993f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93891638993f, replyNumber=0, likeNumber=70, createdTime=2019-08-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93891638993f, moduleTitle=成纤维细胞生长因子受体酪氨酸激酶抑制剂E7090治疗胆管癌，获得日本厚生劳动省的Sakigake指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93891638993f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039894, encodeId=65b520398943c, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Blood：血栓性微血管病变是BCR-ABL1酪氨酸激酶抑制剂帕纳替尼引发心血管毒性的原因之一, objectType=article, longId=159627, objectId=aaa415962ed1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aaa415962ed1, replyNumber=0, likeNumber=66, createdTime=2019-02-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aaa415962ed1, moduleTitle=Blood：血栓性微血管病变是BCR-ABL1酪氨酸激酶抑制剂帕纳替尼引发心血管毒性的原因之一, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aaa415962ed1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039899, encodeId=71ea203989972, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Xynomic Research Institute：一系列有效的RET激酶抑制剂已被成功设计, objectType=article, longId=177981, objectId=ed811e798192, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed811e798192, replyNumber=0, likeNumber=69, createdTime=2019-12-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed811e798192, moduleTitle=Xynomic Research Institute：一系列有效的RET激酶抑制剂已被成功设计, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed811e798192)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039897, encodeId=576a203989ed8, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=阿斯利康的酪氨酸激酶抑制剂Calquence在III期白血病试验中达到终点, objectType=article, longId=167833, objectId=1f1d16e833ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f1d16e833ae, replyNumber=0, likeNumber=81, createdTime=2019-10-30, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f1d16e833ae, moduleTitle=阿斯利康的酪氨酸激酶抑制剂Calquence在III期白血病试验中达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f1d16e833ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039892, encodeId=ea4220398923a, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Life Sci：酪氨酸激酶抑制剂伊马替尼能够调节去势难治性前列腺癌细胞的生存和凋亡, objectType=article, longId=157981, objectId=5bcd15e9816b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bcd15e9816b, replyNumber=0, likeNumber=105, createdTime=2019-12-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bcd15e9816b, moduleTitle=Life Sci：酪氨酸激酶抑制剂伊马替尼能够调节去势难治性前列腺癌细胞的生存和凋亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bcd15e9816b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039888, encodeId=947d2039888dc, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=JCC： JAK激酶抑制剂Peficitinib在治疗中重度UC中有良好效果, objectType=article, longId=153224, objectId=b6d91532243b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6d91532243b, replyNumber=0, likeNumber=61, createdTime=2019-04-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6d91532243b, moduleTitle=JCC： JAK激酶抑制剂Peficitinib在治疗中重度UC中有良好效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6d91532243b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

激酶抑制剂

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者

2021-03-10

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌

2020-09-08

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

多激酶抑制剂ON 123300治疗复发/难治性晚期癌症：即将开展I期临床研究

2021-11-10

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Clin Cancer Res：WEE1激酶抑制剂adavosertib联合化疗治疗TP53突变型卵巢癌

2020-09-11

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

英国NICE推荐将辉瑞的细胞周期蛋白依赖性激酶抑制剂Ibrance用于治疗晚期或转移性乳腺癌

2019-12-13

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Seattle Genetics的酪氨酸激酶抑制剂tucatinib治疗晚期或转移性乳腺癌临床试验成功

2020-06-05

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗

2020-12-29

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

酪氨酸激酶抑制剂治疗胃肠间质瘤不良反应及处理共识

2020-04-11

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Ann Rheum Dis：Janus激酶抑制剂对类风湿性关节炎患者心血管事件风险的影响

2019-07-24

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Lancet oncol：第三代酪氨酸激酶抑制剂（lazertinib）治疗晚期NSCLC

2020-07-22

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Sci Rep：细胞减灭肾切除术围术期使用酪氨酸激酶抑制剂的相关并发症研究

2020-06-21

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定

2019-12-27

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

J Thromb Haemost：接受细胞周期依赖性激酶抑制剂治疗的乳腺癌患者静脉血栓栓塞风险

2020-03-28

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

NICE推荐将激酶抑制剂neratinib用作乳腺癌的新辅助治疗

2019-10-05

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

成纤维细胞生长因子受体酪氨酸激酶抑制剂E7090治疗胆管癌，获得日本厚生劳动省的Sakigake指定

2019-08-09

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Blood：血栓性微血管病变是BCR-ABL1酪氨酸激酶抑制剂帕纳替尼引发心血管毒性的原因之一

2019-02-24

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Xynomic Research Institute：一系列有效的RET激酶抑制剂已被成功设计

2019-12-27

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

阿斯利康的酪氨酸激酶抑制剂Calquence在III期白血病试验中达到终点

2019-10-30

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Life Sci：酪氨酸激酶抑制剂伊马替尼能够调节去势难治性前列腺癌细胞的生存和凋亡

2019-12-06

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

JCC： JAK激酶抑制剂Peficitinib在治疗中重度UC中有良好效果

2019-04-12

科室
- - 订阅+
  - 更多科室
工具
服务